| Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors E Liu, D Marin, P Banerjee, HA Macapinlac, P Thompson, R Basar, ... New England Journal of Medicine 382 (6), 545-553, 2020 | 1770 | 2020 |
| Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia PA Thompson, CS Tam, SM O’Brien, WG Wierda, F Stingo, W Plunkett, ... Blood, The Journal of the American Society of Hematology 127 (3), 303-309, 2016 | 635 | 2016 |
| Ibrutinib and venetoclax for first-line treatment of CLL N Jain, M Keating, P Thompson, A Ferrajoli, J Burger, G Borthakur, ... New England Journal of Medicine 380 (22), 2095-2103, 2019 | 531 | 2019 |
| Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies R Guièze, VM Liu, D Rosebrock, AA Jourdain, M Hernández-Sánchez, ... Cancer cell 36 (4), 369-384. e13, 2019 | 295 | 2019 |
| Complex karyotype is a stronger predictor than del (17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib‐based … PA Thompson, SM O'Brien, WG Wierda, A Ferrajoli, F Stingo, SC Smith, ... Cancer 121 (20), 3612-3621, 2015 | 294 | 2015 |
| 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial CD DiNardo, A Maiti, CR Rausch, N Pemmaraju, K Naqvi, NG Daver, ... The Lancet Haematology 7 (10), e724-e736, 2020 | 279 | 2020 |
| Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia JA Burger, M Sivina, N Jain, E Kim, T Kadia, Z Estrov, ... Blood, The Journal of the American Society of Hematology 133 (10), 1011-1019, 2019 | 263 | 2019 |
| Diagnosis and treatment of chronic myeloid leukemia in 2015 PA Thompson, HM Kantarjian, JE Cortes Mayo Clinic Proceedings 90 (10), 1440-1454, 2015 | 206 | 2015 |
| Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL PA Thompson, WG Wierda Blood, The Journal of the American Society of Hematology 127 (3), 279-286, 2016 | 155 | 2016 |
| Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study PA Thompson, V Lévy, CS Tam, C Al Nawakil, FX Goudot, A Quinquenel, ... British journal of haematology 175 (3), 462-466, 2016 | 145 | 2016 |
| Results of a phase II study of crenolanib in relapsed/refractory acute myeloid leukemia patients (Pts) with activating FLT3 mutations JK Randhawa, HM Kantarjian, G Borthakur, PA Thompson, M Konopleva, ... Blood 124 (21), 389, 2014 | 143 | 2014 |
| Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study F Ravandi, R Assi, N Daver, CB Benton, T Kadia, PA Thompson, ... The Lancet Haematology 6 (9), e480-e488, 2019 | 133 | 2019 |
| Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway K Kondo, H Shaim, PA Thompson, JA Burger, M Keating, Z Estrov, ... Leukemia 32 (4), 960-970, 2018 | 133 | 2018 |
| Long‐term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib P Jain, PA Thompson, M Keating, Z Estrov, A Ferrajoli, N Jain, ... Cancer 123 (12), 2268-2273, 2017 | 131 | 2017 |
| Long‐term follow‐up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic‐phase chronic myeloid leukemia K Naqvi, E Jabbour, J Skinner, K Anderson, S Dellasala, M Yilmaz, ... Cancer 126 (1), 67-75, 2020 | 123 | 2020 |
| Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia FP Tambaro, H Singh, E Jones, M Rytting, KM Mahadeo, P Thompson, ... Leukemia 35 (11), 3282-3286, 2021 | 121 | 2021 |
| Effusion-associated anaplastic large cell lymphoma of the breast: time for it to be defined as a distinct clinico-pathological entity PA Thompson, S Lade, H Webster, G Ryan, HM Prince haematologica 95 (11), 1977, 2010 | 118 | 2010 |
| Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens A Maiti, CR Rausch, JE Cortes, N Pemmaraju, NG Daver, F Ravandi, ... Haematologica 106 (3), 894, 2020 | 116 | 2020 |
| Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia A Maiti, CD DiNardo, NG Daver, CR Rausch, F Ravandi, TM Kadia, ... Blood cancer journal 11 (2), 25, 2021 | 113 | 2021 |
| A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia LS Chen, P Bose, ND Cruz, Y Jiang, Q Wu, PA Thompson, S Feng, ... Blood, The Journal of the American Society of Hematology 132 (21), 2249-2259, 2018 | 111 | 2018 |
